Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial

Platelet Inhibition ◽

P2y12 Receptor ◽

Coronary Syndromes ◽

Baseline Characteristics

Ticagrelor: Oral Reversible P2Y12 Receptor Antagonist for the Management of Acute Coronary Syndromes

Clinical Therapeutics ◽

10.1016/j.clinthera.2012.04.005 ◽

2012 ◽

Vol 34 (6) ◽

pp. 1209-1220 ◽

Cited By ~ 18

Author(s):

Judy W.M. Cheng

Keyword(s):

Receptor Antagonist ◽

P2y12 Receptor ◽

Role of Prasugrel, a Novel P2Y12 Receptor Antagonist, in the Management of Acute Coronary Syndromes

American Journal of Cardiovascular Drugs ◽

10.2165/1131209-000000000-00000 ◽

2009 ◽

Vol 9 (4) ◽

pp. 213-229 ◽

Cited By ~ 22

Author(s):

William L. Baker ◽

C. Michael White

Keyword(s):

Receptor Antagonist ◽

P2y12 Receptor ◽

Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial

European Heart Journal Acute Cardiovascular Care ◽

10.1177/2048872615584076 ◽

2015 ◽

Vol 5 (3) ◽

pp. 282-288 ◽

Cited By ~ 2

Author(s):

Uwe Zeymer ◽

Gilles Montalescot ◽

Diego Ardissino ◽

Leonardo Bolognese ◽

Peter Clemmensen ◽

...

Keyword(s):

Receptor Antagonist ◽

P2y12 Receptor ◽

Optimal Timing ◽

Antagonist Therapy ◽

Lessons Learnt ◽

Coronary Syndromes ◽

St Elevation ◽

Timing Of Initiation

THE PLATELET INHIBITION AND PATIENT OUTCOMES TRIAL IS REPRESENTATIVE OF PATIENTS WITH ACUTE CORONARY SYNDROMES IN A NATIONAL HEART REGISTRY

10.1016/s0735-1097(10)61047-9 ◽

2010 ◽

Vol 55 (10) ◽

pp. A112.E1046 ◽

Cited By ~ 2

Author(s):

Ulf Stenestrand ◽

Saga Johansson ◽

Magnus Janzon ◽

Lars Wallentin

Keyword(s):

Patient Outcomes ◽

Platelet Inhibition ◽

National Heart ◽

PRIOR SMOKING STATUS, CLINICAL OUTCOMES, AND THE COMPARISON OF TICAGRELOR WITH CLOPIDOGREL IN ACUTE CORONARY SYNDROMES – INSIGHTS FROM THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL

10.1016/s0735-1097(12)60496-3 ◽

2012 ◽

Vol 59 (13) ◽

pp. E495

Author(s):

Jan Hein Cornel ◽

Richard Becker ◽

Shaun Goodman ◽

Steen Husted ◽

Hugo Katus ◽

...

Keyword(s):

Clinical Outcomes ◽

Patient Outcomes ◽

Smoking Status ◽

Platelet Inhibition ◽

THE EFFICACY AND SAFETY OF TICAGRELOR AS COMPARED TO CLOPIDOGREL, WITH AND WITHOUT A GLYCOPROTEIN IIB/IIIA INHIBITOR IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PERCUTANEOUS INTERVENTION: A PLATO (STUDY OF PLATELET INHIBITION AND PATIENT OUTCOMES) ANALYSIS

10.1016/s0735-1097(13)61858-6 ◽

2013 ◽

Vol 61 (10) ◽

pp. E1858 ◽

Cited By ~ 1

Author(s):

Sameer Bansilal ◽

Stephen Wiviott ◽

Richard Becker ◽

Robert Harrington ◽

Anders Himmelmann ◽

...

Keyword(s):

Patient Outcomes ◽

Platelet Inhibition ◽

Percutaneous Intervention ◽

Efficacy And Safety ◽

Outcomes Analysis ◽

Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial

Journal of the American Heart Association ◽

10.1161/jaha.117.007009 ◽

2018 ◽

Vol 7 (2) ◽

Cited By ~ 1

Author(s):

Thor Ueland ◽

Axel Åkerblom ◽

Tatevik Ghukasyan ◽

Annika E. Michelsen ◽

Pål Aukrust ◽

...

Keyword(s):

Patient Outcomes ◽

Major Bleeding ◽

Platelet Inhibition ◽

Cardiovascular Outcomes ◽

The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial

10.1016/j.jacc.2010.11.056 ◽

2011 ◽

Vol 57 (19) ◽

pp. 1908-1916 ◽

Cited By ~ 83

Author(s):

Benjamin M. Scirica ◽

Christopher P. Cannon ◽

Håkan Emanuelsson ◽

Eric L. Michelson ◽

Robert A. Harrington ◽

...

Keyword(s):

Patient Outcomes ◽

Platelet Inhibition ◽

ISCHEMIC AND BLEEDING OUTCOMES AFTER CORONARY ARTERY BYPASS GRAFTING AMONG PATIENTS INITIALLY TREATED WITH A P2Y12 RECEPTOR ANTAGONIST FOR ACUTE CORONARY SYNDROMES - INSIGHTS ON TIMING OF DISCONTINUATION OF TICAGRELOR AND CLOPIDOGREL PRIOR TO SURGERY

Canadian Journal of Cardiology ◽

10.1016/j.cjca.2016.07.407 ◽

2016 ◽

Vol 32 (10) ◽

pp. S252

Author(s):

J.J. Russo ◽

T.E. James ◽

M. Ruel ◽

J. Dupuis ◽

K. Singh ◽

...

Keyword(s):

Coronary Artery ◽

Coronary Artery Bypass Grafting ◽

Receptor Antagonist ◽

Coronary Artery Bypass ◽

Artery Bypass ◽

Bypass Grafting ◽

Artery Bypass Grafting ◽

CXC MOTIF LIGAND 16: A NOVEL, INDEPENDENT PREDICTOR OF CARDIOVASCULAR DEATH AND MORBIDITY IN ACUTE CORONARY SYNDROMES - A SUBSTUDY OF THE PLATELET INHIBITION AND PATIENT OUTCOMES TRIAL

10.1016/s0735-1097(19)30680-1 ◽

2019 ◽

Vol 73 (9) ◽

pp. 71

Author(s):

Thomas Andersen ◽

Lars Wallentin ◽

Axel Åkerblom ◽

Thor Ueland ◽

Pal Aukrust ◽

...

Keyword(s):

Patient Outcomes ◽

Independent Predictor ◽

Platelet Inhibition ◽

Cardiovascular Death ◽